1. Home
  2. CHRS vs ACU Comparison

CHRS vs ACU Comparison

Compare CHRS & ACU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRS
  • ACU
  • Stock Information
  • Founded
  • CHRS 2010
  • ACU 1867
  • Country
  • CHRS United States
  • ACU United States
  • Employees
  • CHRS N/A
  • ACU N/A
  • Industry
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • ACU Industrial Machinery/Components
  • Sector
  • CHRS Health Care
  • ACU Consumer Discretionary
  • Exchange
  • CHRS Nasdaq
  • ACU Nasdaq
  • Market Cap
  • CHRS 159.2M
  • ACU 145.9M
  • IPO Year
  • CHRS 2014
  • ACU N/A
  • Fundamental
  • Price
  • CHRS $1.35
  • ACU $41.00
  • Analyst Decision
  • CHRS Strong Buy
  • ACU
  • Analyst Count
  • CHRS 4
  • ACU 0
  • Target Price
  • CHRS $4.51
  • ACU N/A
  • AVG Volume (30 Days)
  • CHRS 1.2M
  • ACU 10.3K
  • Earning Date
  • CHRS 11-05-2025
  • ACU 10-17-2025
  • Dividend Yield
  • CHRS N/A
  • ACU 1.55%
  • EPS Growth
  • CHRS N/A
  • ACU N/A
  • EPS
  • CHRS 1.55
  • ACU 2.55
  • Revenue
  • CHRS $272,209,000.00
  • ACU $194,061,991.00
  • Revenue This Year
  • CHRS N/A
  • ACU $4.69
  • Revenue Next Year
  • CHRS $109.48
  • ACU $6.15
  • P/E Ratio
  • CHRS $0.87
  • ACU $16.22
  • Revenue Growth
  • CHRS 52.33
  • ACU 0.70
  • 52 Week Low
  • CHRS $0.66
  • ACU $34.35
  • 52 Week High
  • CHRS $2.43
  • ACU $45.42
  • Technical
  • Relative Strength Index (RSI)
  • CHRS 64.99
  • ACU 45.78
  • Support Level
  • CHRS $1.23
  • ACU $40.44
  • Resistance Level
  • CHRS $1.40
  • ACU $43.71
  • Average True Range (ATR)
  • CHRS 0.08
  • ACU 1.45
  • MACD
  • CHRS -0.00
  • ACU -0.25
  • Stochastic Oscillator
  • CHRS 72.13
  • ACU 11.64

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

About ACU Acme United Corporation.

Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.

Share on Social Networks: